Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
1 study found for:    18508296 [PUBMED-IDS]
Show Display Options
Rank Status Study
1 Completed A Randomized Trial of 24-Week Versus 48-Week Courses of Peginterferon Plus Ribavirin for HCV Genotype-1 Patients
Conditions: Chronic Hepatitis C;   Genotype
Interventions: Drug: pegylated interferon alpha 2a and ribavirin;   Drug: Pegylated interferon alfa-2a and ribavirin

Indicates status has not been verified in more than two years